# US 2006/0151899 A1 · Process for producing drug ultramicroparticle and apparatus therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0151899 A1
- Document ID: US20060151899A1
- Status: Published application
- Kind: A1
- Application number: 10/563,101
- Filed: 2004-08-04
- Published: 2006-07-13
- Earliest claimed: 2004-08-04
- Inventors: Akira Kato; Takehiro Yamaguchi; Teruko Nomura; Katsumi Onai
- Web page: https://patentgrep.com/patent/US20060151899A1

## CPC

- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5192: {Processes}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides fine drug particles with submicron sizes excellent in long-term dispersibility. Specifically, it provides a method for producing ultrafine drug particles having an average particle size of 10 nm to 1000 nm, by 1) dissolving a drug in a good solvent or a mixture of good solvents to prepare a drug-containing solution; 2) mixing the drug-containing solution with a solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents; and 3) subjecting the prepared mixture directly to emulsification under a set processing pressure using a high-pressure homogenizer without carrying out a pretreatment step for adjusting the drug to have an average particle size of 100 μm or less, and an apparatus for producing the particles.

## Claims

### Claim 1

A method of producing ultrafine drug particles having an average particle size of 10 nm to 1000 nm, comprising the steps of 1) dissolving a drug in at least one good solvent or a mixture of good solvents to prepare a drug-containing solution; 2) mixing the drug-containing solution with a solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents; and 3) subjecting the prepared mixture directly to emulsification under a set processing pressure using a high-pressure homogenizer, without carrying out any pretreatment step for adjusting the drug to have an average particle size of 100 μm or less.

### Claim 2 (depends on 1)

The production method according to claim 1, further comprising the steps of circulating the solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents through a channel in the high-pressure homogenizer, and adding the drug-containing solution to the circulating miscible solvent to thereby mix them.

### Claim 3 (depends on 1)

The production method according to claim 1, wherein the drug is an insoluble drug having a solubility in water of 1 mg/ml or less.

### Claim 4 (depends on 1)

The production method according to claim 1, further comprising dissolving a dispersing agent in a solvent of at least one of 1) the drug-containing solution in a good solvent or a mixture of good solvents and 2) the solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents.

### Claim 5 (depends on 4)

The production method according to claim 4, wherein a concentration of the dispersing agent in the solvent in which the dispersing agent is dissolved is 0.01% to 50% (W/V).

### Claim 6 (depends on 4)

The production method according to claim 4, wherein the dispersing agent is polyoxyethylene polyoxypropylene glycol, lecithin, gelatin and/or polyvinylpyrrolidone.

### Claim 7 (depends on 1)

The production method according to claim 1, wherein, in the step of mixing the drug-containing solution with a solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents, the amount of the drug-containing solution is 0.01% to 50% (V/V) to the amount of the solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution.

### Claim 8 (depends on 1)

The production method according to claim 1, wherein the average particle size is 100 nm to 400 nm.

### Claim 9 (depends on 1)

The production method according to claim 1, wherein the high-pressure homogenizer is a Microfluidizer, a piston-gap homogenizer, a Manton Gaulin Homogenizer, or a Nanomiser.

### Claim 10 (depends on 9)

The production method according to claim 9, wherein the high-pressure homogenizer is a Microfluidizer or a Nanomiser.

### Claim 11 (depends on 1)

The production method according to claim 1, wherein the drug is one of antitumor drugs, antibiotics, anti-inflammatory drugs, analgesics, drugs for treating osteoporosis, hypolipidemic drugs, antibacterial drugs, sedative drugs, tranquilizers, antiepileptic drugs, antidepressants, drugs for treating digestive system diseases, drugs for treating allergic diseases, antihypertensive drugs, antiarteriosclerosis drugs, antidiabetic drugs, hormone drugs and lipid soluble vitamin preparations.

### Claim 12 (depends on 1)

The production method according to claim 1, wherein the high-pressure homogenizer is used at a set processing pressure of 500 to 40000 psi.

### Claim 13 (depends on 12)

The production method according to claim 12, wherein the high-pressure homogenizer is a Microfluidizer and wherein the set processing pressure is 1000 to 6000 psi.

### Claim 14 (depends on 12)

The production method according to claim 12, wherein the high-pressure homogenizer is a Nanomiser and wherein the set processing pressure is 6000 to 20000 psi.

### Claim 15

A method of producing a suspension of ultrafine drug particles or powdered ultrafine drug particles in an arbitrary concentration, the ultrafine drug particles having an average particle size of 10 nm to 1000 nm, comprising the steps of 1) dissolving a drug in a good solvent or a mixture of good solvents to prepare a drug-containing solution; 2) mixing the drug-containing solution with a solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents; 3) subjecting the prepared mixture directly to emulsification under a set processing pressure using a high-pressure homogenizer without carrying out a pretreatment step for adjusting the drug to have an average particle size of 100 μm or less; and 4) removing part or all of the solvent from the suspension of ultrafine drug particles after the treatment with the high-pressure homogenizer.

### Claim 16 (depends on 15)

The production method according to claim 15, further comprising the steps of circulating the solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents through a channel in the high-pressure homogenizer, and adding the drug-containing solution to the circulating miscible solvent to thereby mix them.

### Claim 17 (depends on 15)

The production method according to claim 15, wherein the step of removing part or all of the solvent from the suspension of ultrafine drug particles after the treatment with the high-pressure homogenizer is freeze-drying.

### Claim 18

A high-pressure homogenizer equipped with an online injector, comprising a high-pressure homogenizer and an injector, the high-pressure homogenizer shown in the following FIG. 1 comprising a reservoir, a booster pump and an emulsifier, being connected via thin tubes, the injector being so configured as to feed a drug-containing solution containing a drug dissolved in a good solvent or a mixture of good solvents, the injector being integrated into the high-pressure homogenizer at any position of a channel for a circulating fluid in the thin tubes extending from the reservoir to the emulsifier.

### Claim 19 (depends on 18)

The high-pressure homogenizer equipped with an online injector according to claim 18, wherein the injector is integrated at any position of a channel in the thin tube connecting between the reservoir and the booster pump as shown in the following FIG. 2.

### Claim 20 (depends on 18)

The high-pressure homogenizer equipped with an online injector according to claim 18, wherein the injector is integrated at any position of a channel in the thin tube connecting between the booster pump and the emulsifier as shown in the following FIG. 3.

### Claim 21 (depends on 18)

The high-pressure homogenizer equipped with an online injector according to claim 18, wherein the injector is integrated at any position of a channel in the thin tubes via a joint and/or a mixer.

### Claim 22 (depends on 18)

The high-pressure homogenizer equipped with an online injector according to claim 18, further comprising a regulator for controlling the temperature of the circulating fluid and/or the drug-containing solution, the regulator being integrated into part or all of the emulsifier and/or the thin tubes.

### Claim 23 (depends on 2)

The production method according to claim 2, wherein the high-pressure homogenizer is the high-pressure homogenizer equipped with an online injector.

### Claim 24 (depends on 18)

A method of producing ultrafine drug particles having an average particle size of 10 nm to 1000 nm, comprising the steps of 1) dissolving a drug in a good solvent or a mixture of good solvents to prepare a drug-containing solution; 2) circulating a solvent in a channel in the thin tubes of the high-pressure homogenizer equipped with an online injector of claim 18, the solvent being a poor solvent or a mixture of poor solvents for the drug and being miscible with the drug-containing solution in the good solvent or a mixture of good solvents; 3) feeding the drug-containing solution through the online injector to thereby mix the drug-containing solution with the circulating miscible solvent; and 4) directly emulsifying the resulting mixture online under a set processing pressure using the high-pressure homogenizer.

### Claim 25 (depends on 18)

Use of the high-pressure homogenizer equipped with an online injector of claim 18 for emulsification of a drug-containing solution.
